Lakewood-Amedex Biotherapeutics Inc. SEC filings LABT
Lakewood-Amedex Biotherapeutics Inc. has 44 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 29, 2026 | Sep 22, 2026 |
| EFFECT | Filing | Sep 24, 2026 | — |
| S-1 | Registration statement | Sep 18, 2026 | — |
| DRS | Filing | Aug 24, 2026 | — |
| 424B3 | Prospectus | Aug 17, 2026 | — |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| DEFA14A | Additional proxy material | Aug 10, 2026 | — |
| DEF 14A | Proxy statement | Aug 10, 2026 | Sep 22, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 15, 2026 | Jul 15, 2026 |
| 424B3 | Prospectus | Jun 22, 2026 | — |
| 424B3 | Prospectus | Jun 22, 2026 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jun 17, 2026 | Jun 15, 2026 |
| 424B3 | Prospectus | May 26, 2026 | — |
| 424B3 | Prospectus | May 26, 2026 | — |
| 10-Q | Quarterly report | May 22, 2026 | Mar 31, 2026 |
| 424B4 | Prospectus | May 14, 2026 | — |
| EFFECT | Filing | May 13, 2026 | — |
| CORRESP | Letter to the SEC | May 12, 2026 | — |
| UPLOAD | Letter from the SEC | May 8, 2026 | — |
| S-1 | Registration statement | May 1, 2026 | — |
| 424B3 | Prospectus | Apr 30, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Apr 28, 2026 | Apr 24, 2026 |
| 424B4 | Prospectus | Apr 23, 2026 | — |
| CERT | Filing | Apr 22, 2026 | — |
| EFFECT | Filing | Apr 17, 2026 | — |
| 8-A12B | For registration of certain classes | Apr 17, 2026 | — |
| S-1/A | Amended registration statement | Apr 6, 2026 | — |
| S-1/A | Amended registration statement | Apr 1, 2026 | — |
| S-1/A | Amended registration statement | Mar 11, 2026 | — |
| S-1/A | Amended registration statement | Feb 13, 2026 | — |
| S-1/A | Amended registration statement | Feb 5, 2026 | — |
| S-1 | Registration statement | Jan 9, 2026 | — |
| DRS/A | Filing | Oct 17, 2025 | — |
| DRS | Filing | Jul 31, 2025 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LABT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- University Park, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.